Melanoma Program Expands, Adds Expertise
Melanoma program has grown more than five-fold over the last
decade, with more than five hundred new melanoma patients seen each
year. Program co-directors Nancy Thomas, MD, PhD, and David Ollila,
MD, see this growth as the result of expanding expertise through
strategic hires, a broad range of dermatologic and surgical
expertise, and a strong portfolio of clinical trials of systemic
therapies for melanoma.
building depth in surgical oncology, Thomas and Ollila are very
pleased with several recent hires in other disciplines.“Dr. Dan
Zedek is an outstanding dermatopathologist whose expertise adds to
our ability to accurately diagnose and stage cutaneous malignancies
and Drs. Patricia Mauro and Craig Burkhart have helped us expand
our pigmented lesion program. Dr. Brad Merritt is running a very
busy Moh’s surgery program. And now, with the addition of Dr.
Puneet Jolly, we have a full complement of dermatologic expertise
to assist patients and referring physicians," they explain.
Stergios Moschos is a melanoma medical
oncologist-physician/scientist who also recently joined us from the
University of Pittsburgh Melanoma program, where he was involved in
the identification of molecules that play a role in melanoma
development in addition to his involvement as a clinical researcher
in investigator-initiated and pharma-sponsored trials testing
compounds, such as vemurafenib that led to its FDA approval in 2011
for metastatic melanoma."
Melanoma Program's website.
UNC Physicians Advocate for Laws Preventing Teenage
Tanning Bed Use
The World Health Organization and all specialty groups
involved with treatment of melanoma have recommended banning indoor
tanning beds for children under 18 years of age.
the proven serious risks of early exposure to indoor tanning bed
radiation, children 13 years of age and older are able to use
indoor tanning beds in North Carolina. Among states that have
indoor tanning laws, North Carolina is one of the least protective.
Dr. David Ollila (Surgical Oncology) and Dr. Craig Burkhart
(Pediatric Dermatology) are hoping to change this. They are
teaming up with North Carolina state legislators and medical and
patient advocacy groups to pass an indoor tanning bed bill that
would ban indoor tanning bed use for children under 18 years of
more about their efforts.
Melanoma Clinical Trials
Phase III Randomized Study of Adjuvant High-Dose
versus Low-Dose Adjuvant Ipilimumab versus Adjuvant High-Dose
Interferon Alpha2b for Completely Resected High-Risk Melanoma
Patients with completely resected melanoma (AJCC IIIB-M1b) will be
randomized 1:1:1 to receive one-year-long therapy.
Two clinical studies testing the combination of BRAF
inhibitor, dabrafenib (GSK211436), and the MEK inhibitor,
trametinib (GSK1120212), in unresectable stage III and stage IV
BRAF-mutant, systemic treatment-naïve melanoma. One study is a multi center phase III study and the
other is an investigator-initiated phase II study in which tumor
biopsies will be collected before treatment and at disease
progression to assess mechanisms that the tumor escapes from
concurrent B-RAF and N-RAS inhibition using a proprietary
UNC-Chapel Hill technology (Kinomemining).
A phase 1 study to evaluate the safety, tolerability,
and efficacy of SCH900353 in subjects with advanced solid tumors;
Melanoma, CRC (MK-8353-001).
Patients with B-RAF inhibitor resistant BRAF mutant melanoma, or
N-RAS mutant metastatic melanoma, or K-RAS mutant colorectal cancer
irrespective of prior therapies are allowed to participate.
Randomized, Phase II Study of MK-3475 versus
Chemotherapy in Patients with Advanced Melanoma.
with metastatic unresectable melanoma who have progressed through
ipilimumab are allowed. If patients get randomized to chemotherapy
they are allowed to crossover to MK-3475 (antibody against PD-1).
To Open Soon: A Phase 1b/2, Multicenter, Open-label Trial to
Evaluate the Safety and Efficacy of Talimogene Laherparepvec
and Ipilimumab Compared to Ipilimumab Alone in Subjects With
Previously Untreated, Unresectable, Stage IIIb-IV Melanoma.
with unresectable melanoma who have not received prior therapy and
have disease that can be injected will receive ONCOVEX
intratumorally plus ipilimumab.
Register Now for the Annual UNC Conference on Melanoma
Chapel Hill, North Carolina at the Friday Center for Continuing
Education on February 6 and 7, 2013, this program primarily targets
Dermatologists, Medical Oncologists, Dermatologic Surgeons,
Surgical Oncologists, General Surgeons, Plastic Surgeons, Physician
Assistants, Nurse Practitioners and other health professionals who
are interested in the treatment of melanoma.
more about the conference and register now.
information about Melanoma clinical trials at UNC, call 919-966-4432.
For more information about Melanoma clinical trials offered
offsite, call 919-966-7359.
information about the Melanoma Program, including how to refer a
the program's website.